Sandoz Limited, Apixaban 2.5mg and 5mg tablets defect
Class 4 medicines defect notification: The MHRA has published a Class 4 Medicines Defect Notification for Apixaban 2.5mg and 5mg tablets.
Published: 26 March 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a Class 4 Medicines Defect Notification for Apixaban 2.5mg and 5mg Tablets.
Sandoz Ltd. have informed the MHRA that the Patient Information Leaflet included in specified batches of Apixaban does not contain up‑to‑date information.
Further information, advice and details of the affected batches can be found on the MHRA website.